tirzepatide consent Semaglutide and Weight Loss Client Form | Editable Weight Loss Consent Template | Glp 1 Medication Consent Informed consent for tirzepatide (Mounjaro®)

When covered, expect PA + lifestyle documentation for oral form

Non-targeted metabolomics analyses showed that platinum-resistant ovarian cancer cells have significantly reduced levels of GSH, which contributes to chemoresistance by forming adducts with cisplatin, leading to reduced intracellular concentrations of the active drug, and cisplatin-GSH adducts also reduce intracellular GSH levels

Importantly, this is a retrospective study and not a randomized controlled trial, which means that there could be reasons why people were prescribed semaglutide vs other treatments that impacted their subsequent likelihood of a AUD diagnosis

Document any hypoglycemic episodes, timing relative to meals and semaglutide dosing, and response to treatment to refine your monitoring and dosing strategy over time